Pharmaceutical Industry ESG: Water, Waste, API Manufacturing and Decarbonisation

India's pharmaceutical industry is the world's third largest by volume, supplying approximately 20% of global generic medicines and exporting to over 200 countries. This global footprint comes with global ESG scrutiny. International buyers, particularly in regulated markets like the EU and US, are increasingly imposing sustainability requirements on their Indian API and formulation suppliers. Combined with India's expanding BRSR framework, the ESG agenda for Indian pharma companies has shifted from optional to urgent.

The Most Material ESG Issues in Pharma

For pharmaceutical companies, particularly API manufacturers, the most material ESG issues differ significantly from general industry. Water pollution from effluent discharge — particularly the release of antibiotics and other active pharmaceutical ingredients into waterways — is the most scrutinised issue internationally, with regulators in the EU and Sweden setting stringent limits. Hazardous waste generation and disposal, including solvent recovery and incineration, is the second major area. Energy intensity of synthesis processes — which are often thermally intensive — drives significant Scope 1 and Scope 2 emissions. And supply chain transparency, particularly for raw materials sourced from China, is an increasingly important governance consideration.

What Pharma Buyers and Regulators Now Ask For

Global pharmaceutical buyers — including multinationals sourcing APIs from Indian manufacturers — are using supplier sustainability assessments (typically through platforms like EcoVadis or CDP Supply Chain) to measure and compare their suppliers. The minimum data requirements now include: effluent quality and treatment standards, GHG emissions intensity per tonne of product, energy consumption and renewable energy percentage, waste generation and hazardous waste disposal methods, and chemical safety management systems. Indian pharma companies that score poorly on these assessments face the risk of being delisted in favour of better-performing competitors.

Carbon Credits and ESG Strategy for Pharma

While the primary ESG priority for pharma companies is operational improvement (particularly effluent treatment and energy efficiency), carbon credits play a role in addressing residual Scope 1 and 2 emissions that cannot be eliminated in the short term through operational changes alone. I-RECs for renewable electricity, and high-quality carbon offsets from Gold Standard or VCS projects, allow pharma companies to strengthen their ESG disclosure while longer-term infrastructure investments are underway. Csquare works with pharmaceutical manufacturers to build the ESG data framework, carbon accounting system, and credit procurement strategy needed to meet buyer sustainability requirements.